Deficiency of GDNF Receptor GFRα1 in Alzheimer's Neurons Results in Neuronal Death

We have recently developed aged cortical neuron cultures from autopsied human brains with Alzheimer's disease (AD). During the culturing process, we found that glutamatergic cortical neurons from the AD brain lacked a response to glial cell line-derived neurotrophic factor (GDNF), including no...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of neuroscience Vol. 34; no. 39; pp. 13127 - 13138
Main Authors Konishi, Yoshihiro, Yang, Li-Bang, He, Ping, Lindholm, Kristina, Lu, Bai, Li, Rena, Shen, Yong
Format Journal Article
LanguageEnglish
Published United States Society for Neuroscience 24.09.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We have recently developed aged cortical neuron cultures from autopsied human brains with Alzheimer's disease (AD). During the culturing process, we found that glutamatergic cortical neurons from the AD brain lacked a response to glial cell line-derived neurotrophic factor (GDNF), including no axonal regrowth, and were starting to undergo apoptosis. Here we showed that, in cortical neurons from age- and gender-matched cognitively normal control (NC) subjects (NC neurons), GDNF enhanced the expression of GDNF family receptor subtype α1 (GFRα1), but not the other three subtypes (GFRα2, GFRα3, and GFRα4), whereas GDNF failed to induce GFRα1 expression in cortical neurons from the AD brain (AD neurons). The exogenous introduction of GFRα1, but not of its binding partner α1-neural cell adhesion molecule, or RET into AD neurons restored the effect of GDNF on neuronal survival. Moreover, between NC and AD neurons, the AMPA receptor blocker CNQX and the NMDA receptor blocker AP-5 had opposite effects on the GFRα1 expression induced by GDNF. In NC neurons, the presence of glutamate receptors was necessary for GDNF-linked GFRα1 expression, while in AD neurons the absence of glutamate receptors was required for GFRα1 expression by GDNF stimulation. These results suggest that, in AD neurons, specific impairments of GFRα1, which may be linked to glutamatergic neurotransmission, shed light on developing potential therapeutic strategies for AD by upregulation of GFRα1 expression.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions: Y.K., R.L., and Y.S. designed research; Y.K., L.-B.Y., P.H., and K.L. performed research; Y.K., L.-B.Y., P.H., and R.L. analyzed data; Y.K., L.-B.Y., P.H., K.L., B.L., R.L., and Y.S. wrote the paper.
L.-B. Yang's present address: Department of Pediatrics, University of Minnesota, Minneapolis, MN 55445.
P. He's, K. Lindholm's, and Y. Shen's present address: The Roskamp Institute, Sarasota, FL 34243.
Y. Konishi's present address: Research Unit for Alzheimer's Disease, Department of Clinical Research, National Tottori Medical Center, Tottori 689-0203, Japan.
ISSN:0270-6474
1529-2401
1529-2401
DOI:10.1523/JNEUROSCI.2582-13.2014